Apr 16, 2019 - J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
Apr 16, 2019 - J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019. Hikes 2019 guidance for operational sales and earnings growth. Shares up in pre-market trading.
Apr 16, 2019 - Johnson & Johnson (JNJ) Q1 results: Revenues: $20,021M (+0.1%); Consumer: $3,318M (-2.4%); Pharmaceuticals: $10,244M (+4.1%); Medical Devices: $6,459M (-4.6%).Net Income: $3,749M (-14.2%); EPS: $1
Apr 16, 2019 - Q1 Earnings To Watch For
Apr 16, 2019 - This is the first "full week" of Q1 earnings season, though the influx of reports hitting the tape in the next few weeks to come will be even heavier.
Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Apr 12, 2019 - Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Apr 12, 2019 - Johnson & Johnson (JNJ) could produce exceptional returns because of its solid growth attributes.
Apr 11, 2019 - Let's delve into the Q1 earnings picture that will likely set up the movement of the Dow Jones ETF in the coming days.
Apr 10, 2019 - Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.